Under the terms of the agreement, BioFocus DPI will receive, register, and store selected compounds from Sepracor’s proprietary compound library, and plate and replicate these compounds for a period of three years. Services will be provided by BioFocus DPI’s compound management facility in South San Francisco, US.
Onno van de Stolpe, CEO of Galapagos, said: “Our compound management site has been able to broaden its customer base over the last year, and with this agreement we further expand our list of pharma companies.”